Serum galactomannan levels in the diagnosis of invasive aspergillosis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: In this study, the sensitivity-specificity of galactomannan-enzyme immunoassay (GM-EIA) with a cut-off value of 0.5 for a single, two, or three consecutive positivity in the diagnosis of invasive pulmonary aspergillosis (IPA) in neutropenic patients with hematological malignancy was investigated. Methods: IPA was classified as “proven,” “probable,” or “possible” as described in the guidelines prepared by the European Organization for Research and Treatment of Cancer and Mycoses Study Group.” Serum samples were collected from the patients twice a week throughout their hospitalization. A total of 1,385 serum samples, with an average of 8.3 samples per episode, were examined. Results: Based on the 165 febrile episodes in 106 patients, 80 (48.5%) were classified as IPA (4 proven, 11 probable, 65 possible) and 85 (51.5%) as non-IPA. The sensitivity/ specificity was 100%/27.1% for a single proven/probable IPA with the cut of value of GM-EIA ≥ 0.5, 86.7%/71.8% for two consecutive positive results, and 73.3%/85.9% for three consecutive positive results. Conclusions: With the galactomannan levels measured twice a week, consecutive sensitivity decreased and specificity increased. Therefore, an increase may be obtained in sensitivity-specificity by more frequent monitoring of GM-EIA starting from the first day of positivity is detected.
Abstract
Background/Aims: In this study, the sensitivity-specificity of galactomannan-enzyme immunoassay (GM-EIA) with a cut-off value of 0.5 for a single, two, or three consecutive positivity in the diagnosis of invasive pulmonary aspergillosis (IPA) in neutropenic patients with hematological malignancy was investigated. Methods: IPA was classified as “proven,” “probable,” or “possible” as described in the guidelines prepared by the European Organization for Research and Treatment of Cancer and Mycoses Study Group.” Serum samples were collected from the patients twice a week throughout their hospitalization. A total of 1,385 serum samples, with an average of 8.3 samples per episode, were examined. Results: Based on the 165 febrile episodes in 106 patients, 80 (48.5%) were classified as IPA (4 proven, 11 probable, 65 possible) and 85 (51.5%) as non-IPA. The sensitivity/ specificity was 100%/27.1% for a single proven/probable IPA with the cut of value of GM-EIA ≥ 0.5, 86.7%/71.8% for two consecutive positive results, and 73.3%/85.9% for three consecutive positive results. Conclusions: With the galactomannan levels measured twice a week, consecutive sensitivity decreased and specificity increased. Therefore, an increase may be obtained in sensitivity-specificity by more frequent monitoring of GM-EIA starting from the first day of positivity is detected.
참고문헌 (24)
- Dykewicz CA, "Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients", Clin Infect Dis, 33, pp.139~144 (2001)
- Verweij PE, "Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients", J Clin Microbiol, 33, pp.1912~1914 (1995)
- Pagano L, "The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study", Haematologica, 91, pp.1068~1075 (2006)
- Ozcelik T, "Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy", Mikrobiyol Bul, 43, pp.499~506 (2009)
- Lehrnbecher T, "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital", J Infect, 61, pp.259~265 (2010)
- Arikan S., "Clinical microbiology and infectious diseases. Management of fungal infections", IDrugs, 4, pp.746~749 (2001)
- Mennink-Kersten MA, "Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis", Lancet Infect Dis, 4, pp.349~357 (2004)
- Stynen D, "Rat monoclonal antibodies against Aspergillus galactomannan", Infect Immun, 60, pp.2237~2245 (1992)
- Stynen D, "A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis", J Clin Microbiol, 33, pp.497~500 (1995)
- Yucesoy M, "Investigation of Aspergillus galactomannan levels in antimicrobial agents", Mikrobiyol Bul, 41, pp.565~570 (2007)
- Agca H, "Comparative evaluation of galactomannan optical density indices and culture results in bronchoscopic specimens obtained from neutropenic and non-neutropenic patients", Mycoses, 57, pp.169~175 (2014)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Maertens J, "Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients", Cancer, 115, pp.355~362 (2009)
- Marr KA., "Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy?", Clin Infect Dis, 46, pp.1423~1425 (2008)
- Miceli MH, "Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications", Clin Infect Dis, 46, pp.1412~1422 (2008)
- Pfeiffer CD, "Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis", Clin Infect Dis, 42, pp.1417~1427 (2006)
- Ilstrup DM., "Statistical methods in microbiology", Clin Microbiol Rev, 3, pp.219~226 (1990)
- Machetti M, "Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients", Bone Marrow Transplant, 21, pp.917~921 (1998)
- Maertens J, "Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis", J Clin Microbiol, 37, pp.3223~3228 (1999)
- Maertens J, "Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation", Blood, 97, pp.1604~1610 (2001)
- Maertens J, "Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients", J Infect Dis, 186, pp.1297~1306 (2002)
- Tanriover MD, "Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance", Mycoses, 53, pp.16~25 (2010)
- Rohrlich P, "Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis", Pediatr Infect Dis J, 15, pp.232~237 (1996)
- Marr KA, "Invasive aspergillosis in allogeneic stem cell transplant recipients:changes in epidemiology and risk factors", Blood, 100, pp.4358~4366 (2002)